Literature DB >> 12806274

Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interferon-alpha2b: gene modulatory and antigrowth effects in tumor cells.

Keyur Vyas1, Diana L Brassard, Marc M DeLorenzo, Yaping Sun, Michael J Grace, Ernest C Borden, Douglas W Leaman.   

Abstract

The relative activities of interferon-alpha2b (IFN-alpha2b) and polyethylene glycol(12000)-IFN-alpha2b (PEG-IFN-alpha2b) were assessed in cell culture studies using WM9 melanoma or ACHN renal cell carcinoma cell lines. Interferon-alpha2b and PEG-IFN-alpha2b had identical antiproliferative activities when tested in cell proliferation studies conducted with equivalent antiviral units of each IFN preparation. Neither IFN formulation was effective in inducing apoptosis in WM9 melanoma cells, but both increased slightly the percentage of ACHN cells undergoing apoptosis as assessed by Annexin V staining. Interferon-alpha2b and PEG-IFN-alpha2b both activated signal transducer and activator of transcription complexes, and the duration of complex activation was similar for both IFN formulations. Induction of different IFN-stimulated genes was assessed by Northern blotting and the quantitative real-time reverse transcription-coupled polymerase chain reaction (RT-PCR) in WM9 melanoma, ACHN renal cell carcinoma, U937 lymphoma, and MOLT-4 and Mono Mac 6 leukemia cell lines. Interferon-alpha2b and PEG-IFN-alpha2b had equivalent gene-modulatory activities within each of these tumor cell lines, although cell line-specific induction patterns were observed. When compared with the antiviral 50% inhibitory concentration (IC(50)) values, the dose-dependent gene expression data correlated with cell sensitivity to IFN treatment. Together, the drug comparability and cell sensitivity data suggest a predictive relation between dose, time, antiviral activity, and gene transcription effects. Therefore, although the specific activity of IFN-alpha2b is approximately three times greater than PEG-IFN-alpha2b, the two preparations have identical in vitro biologic activities when applied to cells at equivalent antiviral units.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12806274     DOI: 10.1097/00002371-200305000-00004

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  4 in total

1.  Adjuvant pegylated interferon α-2b therapy for melanoma.

Authors:  Bastian Schilling; Julia Vaubel; Dirk Schadendorf
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

Review 2.  Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow.

Authors:  Fei Xiong; Qi Wang; Guan-Hua Wu; Wen-Zheng Liu; Bing Wang; Yong-Jun Chen
Journal:  Biomark Res       Date:  2022-09-14

3.  Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells.

Authors:  Martin Loignon; Sylvie Perret; John Kelly; Denise Boulais; Brian Cass; Louis Bisson; Fatemeh Afkhamizarreh; Yves Durocher
Journal:  BMC Biotechnol       Date:  2008-08-27       Impact factor: 2.563

4.  Comparative Investigation of Cellular Effects of Polyethylene Glycol (PEG) Derivatives.

Authors:  Ha Pham Le Khanh; Dániel Nemes; Ágnes Rusznyák; Zoltán Ujhelyi; Pálma Fehér; Ferenc Fenyvesi; Judit Váradi; Miklós Vecsernyés; Ildikó Bácskay
Journal:  Polymers (Basel)       Date:  2022-01-11       Impact factor: 4.329

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.